Focused On-demand Library for Myotubularin-related protein 7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y216

UPID:

MTMR7_HUMAN

Alternative names:

Inositol 1,3-bisphosphate phosphatase; Phosphatidylinositol-3-phosphate phosphatase

Alternative UPACC:

Q9Y216; A1L4K9; B4DG87; Q68DX4

Background:

Myotubularin-related protein 7, also known as Inositol 1,3-bisphosphate phosphatase and Phosphatidylinositol-3-phosphate phosphatase, plays a crucial role in cellular processes by dephosphorylating phosphatidylinositol 3-phosphate and inositol 1,3-bisphosphate. This enzymatic activity is pivotal for regulating intracellular signaling pathways.

Therapeutic significance:

Understanding the role of Myotubularin-related protein 7 could open doors to potential therapeutic strategies. Its unique enzymatic functions suggest its involvement in critical signaling pathways, offering a promising target for drug discovery efforts aimed at modulating these pathways for therapeutic benefit.